The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRAL | +419.91% | N/A | N/A | +613% |
| S&P | +12.94% | +86.25% | +13.25% | +26% |
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
A combination of operational improvements and developments at its key rival bolstered the stock recently.
The company has significant potential with its comprehensive cancer test.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $36.19M | 26.3% |
| Gross Profit | -$17.34M | 22.0% |
| Gross Margin | -47.91% | 29.7% |
| Market Cap | $2.13B | 398.9% |
| Market Cap / Employee | $2.13M | 0.0% |
| Employees | 1K | 0.0% |
| Net Income | -$88.98M | 29.2% |
| EBITDA | -$86.31M | 31.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $126.89M | -85.1% |
| Accounts Receivable | $16.28M | 7.0% |
| Inventory | 18.4 | -13.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.57M | -24.0% |
| Short Term Debt | $14.02M | 3.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.21% | 0.0% |
| Return On Invested Capital | -77.62% | -0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$63.63M | 39.7% |
| Operating Free Cash Flow | -$63.25M | 39.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.23 | 0.35 | 0.75 | 0.92 | 481.01% |
| Price to Sales | 4.82 | 6.70 | 13.71 | 15.06 | 287.89% |
| Price to Tangible Book Value | 1.11 | 1.78 | 4.21 | 5.40 | 669.39% |
| Enterprise Value to EBITDA | 0.92 | -2.33 | -14.01 | -19.17 | -840.07% |
| Return on Equity | -65.9% | -62.2% | -17.7% | -16.8% | - |
| Total Debt | $68.14M | $64.32M | $62.16M | $58.59M | -18.84% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
